413 related articles for article (PubMed ID: 13129414)
1. Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies.
Krauth C; Jalilvand N; Welte T; Busse R
Pharmacoeconomics; 2003; 21(14):1001-24. PubMed ID: 13129414
[TBL] [Abstract][Full Text] [Related]
2. Dornase alfa. A review of pharmacoeconomic and quality-of-life aspects of its use in cystic fibrosis.
Goa KL; Lamb H
Pharmacoeconomics; 1997 Sep; 12(3):409-22. PubMed ID: 10170464
[TBL] [Abstract][Full Text] [Related]
3. Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre.
Heimeshoff M; Hollmeyer H; Schreyögg J; Tiemann O; Staab D
Pharmacoeconomics; 2012 Sep; 30(9):763-77. PubMed ID: 22690685
[TBL] [Abstract][Full Text] [Related]
4. rhDNase therapy for the treatment of cystic fibrosis patients with mild to moderate lung disease.
Christopher F; Chase D; Stein K; Milne R
J Clin Pharm Ther; 1999 Dec; 24(6):415-26. PubMed ID: 10651974
[TBL] [Abstract][Full Text] [Related]
5. Nationwide trends in the medical care costs of privately insured patients with cystic fibrosis (CF), 2001-2007.
Briesacher BA; Quittner AL; Fouayzi H; Zhang J; Swensen A
Pediatr Pulmonol; 2011 Aug; 46(8):770-6. PubMed ID: 21465674
[TBL] [Abstract][Full Text] [Related]
6. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
7. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis.
Suri R; Grieve R; Normand C; Metcalfe C; Thompson S; Wallis C; Bush A
Thorax; 2002 Oct; 57(10):841-6. PubMed ID: 12324668
[TBL] [Abstract][Full Text] [Related]
8. Understanding the costs of care for cystic fibrosis: an analysis by age and health state.
van Gool K; Norman R; Delatycki MB; Hall J; Massie J
Value Health; 2013; 16(2):345-55. PubMed ID: 23538187
[TBL] [Abstract][Full Text] [Related]
9. [Socioeconomic evaluation of the effect of rhDNase on the cost of treating infections of the respiratory tract in patients with cystic fibrosis].
von der Schulenburg JM; Greiner W; von der Hardt H
Med Klin (Munich); 1995 Apr; 90(4):220-4. PubMed ID: 7776934
[TBL] [Abstract][Full Text] [Related]
10. Estimating Direct Cost of Cystic Fibrosis Care Using Irish Registry Healthcare Resource Utilisation Data, 2008-2012.
Jackson AD; Jackson AL; Fletcher G; Doyle G; Harrington M; Zhou S; Cullinane F; Gallagher C; McKone E
Pharmacoeconomics; 2017 Oct; 35(10):1087-1101. PubMed ID: 28699086
[TBL] [Abstract][Full Text] [Related]
11. The Economic Burden of Cystic Fibrosis in Germany from a Payer Perspective.
Frey S; Stargardt T; Schneider U; Schreyögg J
Pharmacoeconomics; 2019 Aug; 37(8):1029-1039. PubMed ID: 30949989
[TBL] [Abstract][Full Text] [Related]
12. Innovative assessment of inpatient and pulmonary drug costs for children with cystic fibrosis.
Levy JF; Rosenberg MA; Farrell PM
Pediatr Pulmonol; 2016 Dec; 51(12):1295-1303. PubMed ID: 27740724
[TBL] [Abstract][Full Text] [Related]
13. Use of rhDNase therapy and costs of respiratory-related care in patients with cystic fibrosis.
Ollendorf DA; McGarry LJ; Watrous ML; Oster G
Ann Pharmacother; 2000 Mar; 34(3):304-8. PubMed ID: 10917374
[TBL] [Abstract][Full Text] [Related]
14. Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom.
Angelis A; Kanavos P; López-Bastida J; Linertová R; Nicod E; Serrano-Aguilar P;
BMC Health Serv Res; 2015 Sep; 15():428. PubMed ID: 26416027
[TBL] [Abstract][Full Text] [Related]
15. Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis.
Oster G; Huse DM; Lacey MJ; Regan MM; Fuchs HJ
Ann Pharmacother; 1995 May; 29(5):459-64. PubMed ID: 7655127
[TBL] [Abstract][Full Text] [Related]
16. A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis.
Menzin J; Oster G; Davies L; Drummond MF; Greiner W; Lucioni C; Merot JL; Rossi F; vd Schulenburg JG; Souêtre E
Int J Technol Assess Health Care; 1996; 12(1):52-61. PubMed ID: 8690562
[TBL] [Abstract][Full Text] [Related]
17. Cost of care of patients with cystic fibrosis in The Netherlands in 1990-1.
Wildhagen MF; Verheij JB; Verzijl JG; Hilderink HB; Kooij L; Tijmstra T; ten Kate LP; Gerritsen J; Bakker W; Habbema JD
Thorax; 1996 Mar; 51(3):298-301. PubMed ID: 8779135
[TBL] [Abstract][Full Text] [Related]
18. Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study.
Mlčoch T; Klimeš J; Fila L; Vávrová V; Skalická V; Turnovec M; Krulišová V; Jirčíková J; Zemková D; Dědečková KV; Bílková A; Frühaufová V; Homola L; Friedmannová Z; Drnek R; Dřevínek P; Doležal T; Macek M
Eur J Health Econ; 2017 Jan; 18(1):73-82. PubMed ID: 26743971
[TBL] [Abstract][Full Text] [Related]
19. Cost of home and hospital care for patients with cystic fibrosis followed up in two reference medical centers in France.
Horvais V; Touzet S; François S; Bourdy S; Bellon G; Colin C; Durieu I
Int J Technol Assess Health Care; 2006; 22(4):525-31. PubMed ID: 16984688
[TBL] [Abstract][Full Text] [Related]
20. The role of dornase alfa in the treatment of cystic fibrosis.
Cramer GW; Bosso JA
Ann Pharmacother; 1996 Jun; 30(6):656-61. PubMed ID: 8792953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
